Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 14.7% - Here's What Happened

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 14.7% during mid-day trading on Wednesday . The stock traded as high as $8.49 and last traded at $9.17. 46,019 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 53,619 shares. The stock had previously closed at $7.99.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $20.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Stock Down 14.9%

The company has a 50 day moving average of $8.80 and a two-hundred day moving average of $11.97. The firm has a market cap of $169.70 million, a P/E ratio of -14.51 and a beta of -0.26.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million during the quarter. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Richard Klausner bought 7,900 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $12.00 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now directly owns 42,168 shares in the company, valued at approximately $506,016. This trade represents a 23.05% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely acquired 8,750 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average cost of $12.20 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 35,625 shares in the company, valued at approximately $434,625. This represents a 32.56% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 38,432 shares of company stock valued at $449,508 over the last three months. Insiders own 25.10% of the company's stock.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds have recently bought and sold shares of the business. Graham Capital Management L.P. purchased a new stake in Lyell Immunopharma in the 4th quarter worth about $33,000. RPO LLC acquired a new stake in shares of Lyell Immunopharma during the 4th quarter valued at about $42,000. Wells Fargo & Company MN lifted its holdings in Lyell Immunopharma by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after purchasing an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Lyell Immunopharma during the fourth quarter worth approximately $64,000. Finally, SG Americas Securities LLC grew its holdings in Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after purchasing an additional 59,182 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.